EMBC Company Profile and Key Details

Embecta Corp. has 56.66 million shares outstanding. The public float is 54.77 million shares, elevated short interest at 14.18% of float. This equals 6.68 million shares. The short ratio is 4.83 days. Institutional investors hold 101.24% of the float. Insiders own 1.74%. Kurdikar Devdatt holds 804.92 thousand shares, Elguicze Jacob has 309.14 thousand shares and Mann Jeffrey Z has 262.92 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Short-term trend indicators are bullishly aligned (SMA20 -0.15%, SMA50 -7.86%, SMA200 -14.05%). The stock’s 14-day RSI is 44.62 (neutral), while the ATR of 0.52 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -32.6% below its high and over 13.91% above its low. Average 10-day trading volume of 1.15 million shares is below the 3-month average of 1.84 million, indicating normal recent market interest.

Embecta Corp. (NASDAQ:EMBC) closed at $4.97 USD, gaining $0.01 (0.20%) from the previous close of $4.96. The stock is currently mid-range between its 52-week high and low $2.77 and $15.55. With a market capitalization of about $294.86 million, Embecta Corp. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.79). Key stats such as the average daily volume over the past year has been around 1.86 million shares, volume is running light vs its 52-week average. Headquartered in Parsippany, NJ, Embecta Corp. operates in the Healthcare sector and the Medical - Instruments & Supplies industry. Led by CEO Devdatt Kurdikar, the company employs approximately 1,850 people and listed since March 22, 2022. Embecta Corp. is a medical technology enterprise devoted to enhancing the quality of life and health outcomes for individuals living with diabetes.

Embecta Corp. last paid a dividend of 0.46 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $24.60. This means the shares are trading below this model’s fair value.

Embecta Corp. trades at a P/E ratio of 3.31, slightly below the S&P 500 average, with a price-to-sales ratio of 0.29 and a price-to-book ratio of -0.47 indicating negative book value, which may reflect financial stress. The P/FCF stands at 1.78, also above market averages.

Our AI price prediction model suggests that Embecta Corp. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 17.3%, with price expected at $5.83 by September 10, 2026, within a range of $5.47 to $6.22 3-Month Outlook: Projected fall of -49.7%, reaching $2.50 by November 25, 2026, with a range of $1.69 to $2.91. 1-Year Outlook: Projected loss of -79.28%, with price at $1.03 by August 27, 2027, within a range of $0.00 to $0.00.

Embecta Corp. (NASDAQ:EMBC) shares are flat 3.45% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Embecta Corp. trading at a premium to the broader market with a P/E of 3.31. Analyst sentiment is cautious, with the majority of ratings in Underperform territory and a mean price target of $19.50, suggesting 292.35% upside. Our AI forecast model points to short-term strength (17.3% over two weeks), a medium-term fall (-49.7% over three months), and a longer-term loss (-79.28% over one year), with expected trading ranges indicating moderate volatility.